DE69837012D1 - Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion - Google Patents

Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion

Info

Publication number
DE69837012D1
DE69837012D1 DE69837012T DE69837012T DE69837012D1 DE 69837012 D1 DE69837012 D1 DE 69837012D1 DE 69837012 T DE69837012 T DE 69837012T DE 69837012 T DE69837012 T DE 69837012T DE 69837012 D1 DE69837012 D1 DE 69837012D1
Authority
DE
Germany
Prior art keywords
impregents
preparation
retroviral infection
pathogenic state
hiv retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837012T
Other languages
English (en)
Other versions
DE69837012T2 (de
Inventor
Pierre-Francois Serres
Christophe Geourjon
Gilbert Deleage
Christophe Combet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOMASTAR SARL, NYON, CH
Original Assignee
Mymetics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics SA filed Critical Mymetics SA
Application granted granted Critical
Publication of DE69837012D1 publication Critical patent/DE69837012D1/de
Publication of DE69837012T2 publication Critical patent/DE69837012T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE69837012T 1997-11-17 1998-11-17 Herstellung von Impfstoffen zur Vorbeugung von Pathogenen Zuständen einer HIV retroviralen Infektion Expired - Lifetime DE69837012T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714387A FR2771011B1 (fr) 1997-11-17 1997-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR9714387 1997-11-17
PCT/FR1998/002447 WO1999025377A1 (fr) 1997-11-17 1998-11-17 Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Publications (2)

Publication Number Publication Date
DE69837012D1 true DE69837012D1 (de) 2007-03-22
DE69837012T2 DE69837012T2 (de) 2007-11-29

Family

ID=9513450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837012T Expired - Lifetime DE69837012T2 (de) 1997-11-17 1998-11-17 Herstellung von Impfstoffen zur Vorbeugung von Pathogenen Zuständen einer HIV retroviralen Infektion

Country Status (19)

Country Link
US (3) US6455265B1 (de)
EP (1) EP1034000B1 (de)
JP (1) JP4837823B2 (de)
KR (1) KR20010032210A (de)
CN (1) CN1281371A (de)
AP (1) AP2000001841A0 (de)
AT (1) ATE353017T1 (de)
AU (1) AU1243499A (de)
BR (1) BR9814204A (de)
CA (1) CA2309676C (de)
DE (1) DE69837012T2 (de)
DK (1) DK1034000T3 (de)
EA (1) EA200000528A1 (de)
ES (1) ES2281938T3 (de)
FR (1) FR2771011B1 (de)
IL (2) IL136163A0 (de)
OA (1) OA11522A (de)
PT (1) PT1034000E (de)
WO (1) WO1999025377A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
CN1396178A (zh) * 2002-06-17 2003-02-12 成都阳辉生物科技有限责任公司 抗乙肝病毒等包膜病毒感染的工程多肽及其制备方法
ES2366185T3 (es) * 2003-04-11 2011-10-18 Institut Pasteur Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.
WO2005010033A1 (en) * 2003-07-30 2005-02-03 Mymetics Corporation New soluble and stabilized trimeric form of gp41 polypeptides
WO2006011919A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2004273076B2 (en) * 2003-09-11 2008-02-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1709447B1 (de) * 2003-12-18 2009-06-24 Idexx Laboratories, Inc. Verfahren zum nachweis des felinen immunschwächevirus
CA2556141A1 (en) * 2004-02-19 2005-09-01 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
CA2576930C (en) * 2004-06-30 2011-06-07 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
JP4662988B2 (ja) * 2004-06-30 2011-03-30 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスを検出するための方法および装置
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1879617A1 (de) * 2005-05-02 2008-01-23 Mymetics Corporation Antikörper oder fragment davon mit neutralisierender aktivität gegen hiv, jedoch nicht gegen il2
TWI343180B (en) * 2005-07-01 2011-06-01 Ind Tech Res Inst The acoustic wave sensing-device integrated with micro channels
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
CN1869704B (zh) * 2006-06-14 2010-06-30 厦门大学 快速鉴定与病原菌互作的宿主蛋白的方法
WO2010042760A2 (en) * 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
US8765137B2 (en) 2009-02-06 2014-07-01 Mymetics Corporation Gp41 antigens
BRPI1008721A2 (pt) 2009-02-06 2016-03-08 Inserm Inst Nat De La Santé Et De La Rech Médicale métodos para tratamento terapêutico ou profiláctico de hiv, método profilático, composição terapêutica ou preparação, associação de vacina terapêutica, kit para implantação de método terapêutico
US20120148594A1 (en) * 2009-08-21 2012-06-14 Dana-Farber Cancer Institute, Inc. Mimotopes of hiv and uses thereof
EP2553452B1 (de) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Nachweis des felinen immundefizienzvirus
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
MX358782B (es) 2012-08-30 2018-09-04 Merial Inc Expresión de proteina ksac quimérica y método para producir proteínas solubles mediante alta presión.
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
CN111701016A (zh) * 2020-06-28 2020-09-25 张全志 逆转录病毒原病毒序列在逆转录病毒疫苗设计中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001304A1 (en) * 1991-07-10 1993-01-21 Synbiotics Corporation Synthetic peptides related to fiv-env proteins
ATE183515T1 (de) * 1992-07-20 1999-09-15 Univ Duke Zusammensetzungen die die hiv replikation inhibieren
GB9219936D0 (en) * 1992-09-21 1992-11-04 Pitman Moore Inc Vaccines
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale

Also Published As

Publication number Publication date
DK1034000T3 (da) 2007-06-04
DE69837012T2 (de) 2007-11-29
US7253270B2 (en) 2007-08-07
EP1034000B1 (de) 2007-01-31
US20080003229A1 (en) 2008-01-03
ATE353017T1 (de) 2007-02-15
JP2001524456A (ja) 2001-12-04
CN1281371A (zh) 2001-01-24
BR9814204A (pt) 2000-10-03
CA2309676A1 (fr) 1999-05-27
OA11522A (fr) 2004-02-09
JP4837823B2 (ja) 2011-12-14
US20050048478A9 (en) 2005-03-03
IL136163A0 (en) 2001-05-20
FR2771011A1 (fr) 1999-05-21
IL136163A (en) 2007-07-04
AP2000001841A0 (en) 2000-06-30
CA2309676C (fr) 2012-08-07
EP1034000A1 (de) 2000-09-13
US20040014046A1 (en) 2004-01-22
PT1034000E (pt) 2007-05-31
FR2771011B1 (fr) 2000-01-28
ES2281938T3 (es) 2007-10-01
US7829683B2 (en) 2010-11-09
AU1243499A (en) 1999-06-07
WO1999025377A1 (fr) 1999-05-27
KR20010032210A (ko) 2001-04-16
US6455265B1 (en) 2002-09-24
EA200000528A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
DE69837012D1 (de) Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion
DE69429359T2 (de) Orale zubereitungen von antimykotika
DE60038817D1 (de) Herstellung von cordieritstrukturen mit ultradünnen wänden
DE60018429D1 (de) Herstellung von poly(trimethylenterephthalat)
DE69408679D1 (de) Herstellung von geformten faserstrukturen
DE69737567D1 (de) Herstellung einer lithiumionensekundärbatterie
DE60019960D1 (de) Herstellung von isobutencopolymere
DE59915061D1 (de) Herstellung von strukturierten elektroden
DE59912915D1 (de) Herstellung von 4,4'-Diketo-carotinoiden
DE69732479D1 (de) Herstellung einer feuerfesten ausbesserungsmasse
DK0875579T3 (da) Fremstilling af L(+)-laktat
DE69935165D1 (de) Herstellung von polyolefin
DE69524976T2 (de) Herstellung von [11C] Methyljodid
DE59604181D1 (de) Herstellung von lösbar verbundenen hülsenstücken
DE3752115D1 (de) Herstellung einer Dioxazinverbindung
ATE120718T1 (de) Herstellung von peroxidzusammensetzungen.
DE60016608D1 (de) Herstellung von sulfonylimin-verbindungen
DE69809433T2 (de) Herstellung von avermectin-verbindungen
DE69733607D1 (de) Herstellung von cycloalkyldiarylphosphinen
FI965292A (fi) HIV:tä vastaan suunnattu kolmen aineen yhdistelmä
DE59804303D1 (de) Herstellung von Polyenaldehyden
DE69521513D1 (de) Herstellung von keramischen artikeln
NO965591D0 (no) Kombinasjonsbehandling av HIV-infeksjon
DE69013868D1 (de) Katalytische Herstellung von Cumarin-Verbindungen.
DE69811864D1 (de) Herstellung von bandförmigen werkstücken

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LOMASTAR SARL, NYON, CH